Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 10.7% in April

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 2,500,000 shares, a decrease of 10.7% from the March 31st total of 2,800,000 shares. Based on an average daily volume of 836,100 shares, the days-to-cover ratio is presently 3.0 days.

Analyst Upgrades and Downgrades

ALNY has been the topic of a number of research reports. Wolfe Research assumed coverage on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. They issued a “peer perform” rating on the stock. Citigroup cut their price objective on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Morgan Stanley decreased their target price on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 13th. Chardan Capital cut their price target on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating for the company in a report on Friday, February 16th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $235.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $215.88.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after purchasing an additional 287,064 shares during the last quarter. Wellington Management Group LLP increased its stake in Alnylam Pharmaceuticals by 6.0% in the 3rd quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after acquiring an additional 364,021 shares during the last quarter. Capital International Investors raised its holdings in shares of Alnylam Pharmaceuticals by 15.8% during the 4th quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock worth $686,641,000 after acquiring an additional 488,814 shares in the last quarter. Capital Research Global Investors boosted its position in shares of Alnylam Pharmaceuticals by 5.3% during the 4th quarter. Capital Research Global Investors now owns 2,930,079 shares of the biopharmaceutical company’s stock valued at $560,880,000 after acquiring an additional 146,236 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $390,438,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $147.36 on Tuesday. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $218.88. The business has a 50 day simple moving average of $150.21 and a two-hundred day simple moving average of $165.76. The company has a market capitalization of $18.56 billion, a price-to-earnings ratio of -41.39 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. Alnylam Pharmaceuticals’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.68) EPS. Sell-side analysts anticipate that Alnylam Pharmaceuticals will post -4.46 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.